WallStSmart

Fulgent Genetics Inc (FLGT)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 14009% more annual revenue ($45.20B vs $320.35M). TMO leads profitability with a 15.1% profit margin vs -23.0%. FLGT appears more attractively valued with a PEG of 1.32. TMO earns a higher WallStSmart Score of 62/100 (C+).

FLGT

Hold

40

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 7.0Quality: 9.0
Piotroski: 5/9Altman Z: 7.36

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FLGTUndervalued (+54.8%)

Margin of Safety

+54.8%

Fair Value

$50.88

Current Price

$18.14

$32.74 discount

UndervaluedFair: $50.88Overvalued
TMOSignificantly Overvalued (-41.7%)

Margin of Safety

-41.7%

Fair Value

$331.35

Current Price

$472.80

$141.45 premium

UndervaluedFair: $331.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLGT3 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.3610/10

Safe zone — low bankruptcy risk

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$179.15B9/10

Large-cap with strong market position

Areas to Watch

FLGT4 concerns · Avg: 2.3/10
Market CapQuality
$543.87M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-7.0%2/10

ROE of -7.0% — below average capital efficiency

Revenue GrowthGrowth
-3.2%2/10

Revenue declined 3.2%

EPS GrowthGrowth
-98.6%2/10

Earnings declined 98.6%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.624/10

Expensive relative to growth rate

P/E RatioValuation
26.5x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FLGT

The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : FLGT

The primary concerns for FLGT are Market Cap, Return on Equity, Revenue Growth.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

FLGT profiles as a turnaround stock while TMO is a mature play — different risk/reward profiles.

FLGT carries more volatility with a beta of 0.92 — expect wider price swings.

TMO is growing revenue faster at 6.2% — sustainability is the question.

TMO generates stronger free cash flow (816M), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 40/100), backed by strong 15.1% margins. FLGT offers better value entry with a 54.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fulgent Genetics Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?